Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial www.statnews.com/2026/08/19/m... via @statnews.com
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
statnews.com
Top line retatrutide results in TRIUMPH-2 and TRIUMPH-3. Top dose shows 20.8% per protocol weight loss in T2DM. (few % > tirzepatide) In contrast with tirze's SURPASS-4, uncertainty on CV effects of adding glucagon agonism. /1 investor.lilly.com/news-release...
fipco (@fipco) on X
Reassuring for GIP agonism. This seems to meet previous FDA CV safety standard ahead of CV outcomes trial. #tirzepatide https://t.co/cBo21QZmiy https://t.co/SRvuoPegE6
x.com
Anderson, et al. show major expansion of statin eligible individuals 30-59 years old under the new 2026 ACC/AHA/+ lipid guidelines ~18% --> 36% of individuals. A large factor is the 30-year PREVENT-ASCVD risk criteria.👍 /1 jamanetwork.com/journals/jam...
Baricitinib safety data presented at #EULAR2026 for pooled RA-BRIDGE and RA-BRANCH scientific.sparx-ip.net/archiveeular... abstract search link. Arguably VTE and cancer signals persist. Tofa safety trial Rx dropouts 35% for TNF arm, 57% in bari trials. #Jak bsky.app/profile/fipc...
Fipco@fipco.bsky.social · 5mo agoNCT03915964 and NCT04086745 have yet to report. Primary completion date of trial was May 2025. Nearly 4k randomized patients followed multiple years assessing JAKi safety. Potential release this month. #baricitinib bsky.app/profile/fipc...
NCT03915964 and NCT04086745 have yet to report. Primary completion date of trial was May 2025. Nearly 4k randomized patients followed multiple years assessing JAKi safety. Potential release this month. #baricitinib bsky.app/profile/fipc...
Fipco@fipco.bsky.social · 10mo agoAccording to clinicaltrials.gov the baricitinib CV safety trials completed 6 months ago. Perhaps more t's to cross and i's to dot. This EULAR consensus review pointed to these studies as important in assessing JAKi safety. pubmed.ncbi.nlm.nih.gov/36357155/ bsky.app/profile/fipc...
"Pancreatic cancer mRNA vaccine shows lasting results in an early trial: Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later."
Pancreatic cancer mRNA vaccine shows lasting results in an early trial
Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.
nbcnews.com
💬 Editorial: Simulation modeling demonstrates #ApoB-guided statin intensification is cost-effective, identifies more clinically meaningful risk, and aligns with 2026 ACC/AHA guidelines. ja.ma/4cxddfa
A computer simulation found #ApoB-guided intensification of lipid-lowering therapy provides the most QALYs and is highly cost-effective compared to #LDL-C or #nonHDL-C targets. ja.ma/4cxfzKX
New mega-analysis showing statin therapy is associated with reduced risk of AD and related out comes, pubmed.ncbi.nlm.nih.gov/41761642/ @nationallipid.bsky.social @aspcardio.bsky.social @fabyollaveras.bsky.social @menopausesociety.bsky.social @eassociety.bsky.social
Essence-CTA: Does Olezarsen Reduce Noncalcified Coronary Plaque Volume? Check out the results of the 🆕 #ACC26 late-breaking clinical trial: https://bit.ly/4tc0UKH #cvLipids #CardioSky
Ann Marie Navar has more to say on this topic: youtu.be/DRO5kHfcnz0?...
New Lipid Guidelines, Baby!
YouTube video by Ann Marie Navar
youtu.be
AHA/ACC/+ Lipid Guidelines - another notable and welcome change: use of long term risk to guide lipid lowering therapy. 30-year PREVENT-ASCVD risk >=10% support use of lipid lowering therapy. (this adds a large number of 30-59yr olds over prior PCE 5%) x.com/fipco/status...
ApoB recommendations from the 2026 AHA/ACC/+ lipid guidelines. "reasonable to measure" Yay! /1 www.jacc.org/doi/full/10....
In Novo's head to head trial of Cagrisema 2.4/2.4mg compared to Tirzepatide 15mg, Cagrisema did not show non-inferiority on the primary endpoint of weight loss at 84 weeks. ITT weight loss 20.2% v 23.6%, PP 23.0% v 25.5% for C-S v T. REDEFINE-4 www.novonordisk.com/news-and-med...
"Recent research suggests that more people should be screened for a protein called apoB. A growing number of doctors agree." #cardiosky www.nbcnews.com/health/heart...
Is this blood test a better predictor of heart disease than LDL cholesterol?
Recent research suggests that more people should be screened for a protein called apoB. A growing number of doctors agree.
nbcnews.com
Rehman, et al. propose a single risk measure to reflect risk from apoB generally, Lp(a), and TG rich-lipoproteins. "RW-apoB" for "risk weighted". The scale is comparable to current apoB levels. #cardiosky /1 academic.oup.com/eurheartj/ad...
New online! Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies #CardioSky
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Nature Reviews Cardiology, Published online: 23 January 2026; doi:10.1038/s41569-026-01249-zIn this Review, Galli and colleagues discuss the mechanisms and associated biomarkers of traditional and emerging factors responsible for the residual risk of recurrent adverse cardiovascular events in patients with coronary artery disease, with a focus on new pathophysiological insights and the therapeutic implications.
dlvr.it
A TRIUMPH for the GCGR-GLP1R-GIPR triple agonist Retatrutide in P3. Participants with #obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks. Mild dysesthesias noted #weightloss #arthritis investor.lilly.com/news-release...
Open to views of others. I'm hooked based on RCT + supportive trial + limited alternatives. I'm also a supporter of high dose EPA for secondary CV prevention. That's based in part on theory that high achieved EPA drives benefit. That doesn't apply to PISCES... /1 bsky.app/profile/neph...
Nephrology Journal Club@nephjc.bsky.social · 10mo agoMaybe the most shocking study from #KidneyWk. 🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊? www.nephjc.com/news/pisces-fishoil
According to clinicaltrials.gov the baricitinib CV safety trials completed 6 months ago. Perhaps more t's to cross and i's to dot. This EULAR consensus review pointed to these studies as important in assessing JAKi safety. pubmed.ncbi.nlm.nih.gov/36357155/ bsky.app/profile/fipc...
Fipco@fipco.bsky.social · 2y ago-ACHIEVE-1-orforglipron - oral GLP1 in diabetics - 1st phase 3 (April) -RA-BRIDGE/BRANCH-baricitinib - 2nd long term CV safety RCT of JAKinibs after ORAL Surveillance (April '25/Dec '24) -CORALreef HEFH-oral PCSK9i Enlicitide Decanoate MK-0616 ...1st phase 3 (April) /2-fin #cardiosky
The Economist on apoB. ApoB is inexpensive and more accurate than LDL-C. The measures disagree in 30-40% of individuals. www.economist.com/science-and-... #cardiosky
Thoughtful, provocative editorial. Some fair points. Respectfully disagree with apoB/CAC examples. IMO evidence base (including health economics) for these support broader use and are incorporated in some guidelines (apoB: EAS/ESC, CCS, NLA statement) #cardiosky bsky.app/profile/jame...
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure. #KidneyWK @asnkidney.bsky.social ja.ma/4oV4DtU
Shocking first high impact trial of the day. Fish oil reduces CV events in dialysis patients! #Pisces #kidneywk Simultaneous pub in NEJM www.nejm.org/doi/full/10....
The latest empadata dump: @nephroseeker.medsky.social writes up a #NephJC short on the meta analysis www.nephjc.com/news/2025/10...
Empagliflozin, the kidney, and what we still don’t understand — NephJC
NephJC short on an empagliflozin meta-analysis
nephjc.com
• start prevention earlier (than current guidelines suggest) • measure apoB Editorial by Angela Pirillo and Alberico Catapano #cardiosky academic.oup.com/eurheartj/ad...
ICER organization draft: Semaglutide and tirzepatide for obesity are cost effective. For context, a 2014 ACC/AHA task force suggested a less than $50k per QALY threshold as "high value". #cardiosky icer.org/assessment/o...
NATURE-Legacy study compares MR/genetically modeled life long LDL-C and blood pressure lowering (HR 0.32) to short term effects in the HOPE-3 trial (HR 0.71). By Brian Ference, et al. /1 #ESCCongress2025 #cardiosky
"This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P." Analysis of UK Biobank data by Elizabeth Epstein, et al. #cardiosky pubmed.ncbi.nlm.nih.gov/40887080/
Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank - PubMed
This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P. Notably, risk was already elevated at as little...
pubmed.ncbi.nlm.nih.gov
Statin eligibility with PREVENT vs PCE 10 year risk at various thresholds by Sadiya Kahn, et al. jamanetwork.com/journals/jam...
